Trial reportJAMA health forum2026
Cost-Effectiveness of Community-Based Rehabilitation for People With Schizophrenia: A Secondary Analysis of a Cluster Randomized Trial.
Trial report in JAMA health forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Schizophrenia imposes a substantial disease burden in resource-constrained settings such as China, yet rigorous evidence on the cost-effectiveness of community-based rehabilitation (CBR) remains limited. Objective: To evaluate the cost-effectiveness of a group-based CBR intervention plus facility-based care (FBC) compared with FBC alone for adults with schizophrenia in China. Design, Setting, and Participants: This prespecified secondary analysis evaluated a cluster randomized trial conducted across 18 urban and rural subdistricts in Weifang, Shandong Province, China, from March 2023 to October 2024. Participants were community-dwelling, clinically stable adults aged 18 to 59 years with an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis of schizophrenia and illness duration of at least 12 months. Intervention: The CBR program comprised 18 group sessions over 12 months (12 biweekly sessions, then 6 monthly sessions) covering psychoeducation, medication adherence, physical health promotion (including tai chi), life and social skills training, and caregiver support. FBC consisted of psychiatrist-led medication management and monthly consultations. Main Outcomes and Measures: The main outcomes were incremental cost per quality-adjusted life-year (QALY) gained and per-unit improvement in symptom severity (Positive and Negative Syndrome Scale [PANSS]), social functioning (Personal and Social Performance Scale [PSP]), and caregiver burden (Burden Assessment Scale [BAS]), assessed from health care system, multipayer, and societal perspectives. Results: A total of 334 participants were enrolled and randomized; 172 were randomized to CBR plus FBC and 162 to FBC alone. At 12 months, 161 participants (93.6%) and 154 participants (95.0%) were retained, respectively. Mean (SD) baseline age was 46.7 (9.3) years; 180 participants (53.9%) were male; 204 (61.1%) resided in rural areas. CBR was associated with significantly improved clinical outcomes and lower costs at 12 months. Incremental cost-effectiveness ratios indicated savings of $24 636 to $27 847 per QALY gained across perspectives, with $20.70 to $46.90 saved per unit improvement in PANSS, PSP, and BAS scores. The probability of cost-effectiveness ranged from 91.0% to 98.7% for QALYs and exceeded 95% for clinical outcomes at derived threshold values of $24.30 to $52.00 per unit. Sensitivity analyses confirmed robustness. Conclusions and Relevance: In this secondary analysis of a cluster randomized trial, group-based CBR for schizophrenia in China was associated with improved outcomes and a high probability of cost savings, supporting its scaled implementation in resource-constrained settings. Trial Registration: ChiCTR.org.cn Identifier: ChiCTR2200066945.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.